ClinicalTrials.gg
CompletedNCT02215005Updated Aug 13, 2014

Steady State Pharmacokinetics of Telmisartan, Ramipril or the Combination Following Repeated Oral Doses to Healthy Male and Female Volunteers

A Phase 1 interventional study of Telmisartan and Ramipril in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-13.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main objective was to investigate the effect of concurrent dosing of 10 mg ramipril and 80 mg telmisartan on the multiple-dose pharmacokinetics of telmisartan and ramipril. Therefore the relative bioavailability of telmisartan and ramipril given in combination was determined in comparison with either telmisartan or ramipril given alone.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males and females according to the following criteria based upon a complete medical history, including the physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead (ECG), clinical laboratory tests
  • Age ≥18 and ≤55 years
  • (BMI) ≥18.5 and ≤29.9 kg/m2
  • Signed and dated written prior to admission to the study in accordance with Good Clinical Practice and the local legislation

Exclusion criteria

Exclusion Criteria:

  • Any finding of the medical examination (including BP, PR and ) deviating from normal and of clinical relevance
  • Any evidence of a concomitant disease
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of the gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy/ (including allergy to drug or its )
  • Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  • Use of drugs which might reasonably influence the results of the trial (especially unspecific inducing agents like St.John´s wort (Hypericum perforatum) or inhibitors like cimetidine) or drugs that prolong the /QTc interval based on the knowledge at the time of protocol preparation within 10 days prior to administration of trial drug or during the trial
  • Participation in another trial with an drug within two months prior to administration or during the trial
  • Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
  • Alcohol abuse (more than 60 g/day) or inability to stop alcoholic beverages for 24 hours prior to dosing and up to the last sampling time point
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to administration of trial drug or during the trial)
  • Excessive physical activities (within one week prior to administration of trial drug or during the trial)
  • Any laboratory value outside the reference range that is of clinical relevance
  • Inability to comply with dietary regimen of trial site
  • A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
  • A history of additional risk factors for torsade de pointes (e.g., heart failure, hyperkalaemia, hypokalemia, family history of Long QT Syndrome)
  • Any history of relevant low blood pressure
  • Supine blood pressure at screening of systolic \<110 mm Hg and diastolic \<60 mm Hg
  • History of urticaria
  • History of angioneurotic edema
  • Hereditary fructose intolerance
  • Salt and/or volume depletion

For female subjects:

  • Pregnancy or planning to become pregnant during the study or within 1 months of study completion
  • Positive pregnancy test
  • Not willing or unable to use a reliable method of such as implants, injectables, combined oral contraceptives, sterilisation, intrauterine device, double barrier method, sexual abstinence for at least 1 month, or vasectomised partner as only method of contraception for at least 6 months prior to participation in the trial, during and up to 1 month after completion/termination of the trial
  • Chronic use of oral contraception containing ethinyl estradiol as the only method of contraception
  • Currently lactating
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Telmisartan + Ramipril

    5 days qd

    Drug: Telmisartan · Drug: Ramipril

  • Active comparator
    Telmisartan

    5 days qd

    Drug: Telmisartan

  • Active comparator
    Ramipril

    5 days qd

    Drug: Ramipril

Interventions

06

What researchers measure

Primary outcomes

  1. AUCτ,ss (area under the concentration-time curve in plasma at steady state over a uniform dosing interval τ)

    Time frame: up to 72 hours after last drug administration of each treatment

  2. Cmax,ss (maximum measured concentration in plasma at steady state over a uniform dosing interval τ)

    Time frame: up to 72 hours after last drug administration of each treatment

Secondary outcomes

  1. Concentration of the analytes in plasma

    Time frame: 2, 4, and 12 hours after administration of the first dose of each treatment on day 1

  2. pre-dose concentration of the analytes in plasma immediately before the administration of the next dose

    Time frame: pre-dose up to day 5 of each treatment

  3. tmax,ss (time from last dosing to the maximum concentration of the analytes in plasma at steady state)

    Time frame: up to 72 hours after last drug administration of each treatment

  4. Cmin,ss (minimum concentration of the analytes in plasma at steady state over a uniform dosing interval τ)

    Time frame: up to 72 hours after last drug administration of each treatment

  5. Cpre,ss (pre-dose concentration of the analytes in plasma immediately before the administration of the next dose at steady state)

    Time frame: pre-dose up to day 5 of each treatment

  6. Cavg (average concentration of the analytes in plasma at steady state)

    Time frame: up to 72 hours after last drug administration of each treatment

  7. λz,ss (terminal rate constant in plasma at steady state)

    Time frame: up to 72 hours after last drug administration of each treatment

  8. t1/2, ss (terminal half-life of the analyte in plasma at steady state)

    Time frame: up to 72 hours after last drug administration of each treatment

  9. MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration)

    Time frame: up to 72 hours after last drug administration of each treatment

  10. CL/F,ss (apparent clearance of the analyte in plasma at steady state after extravascular multiple dose administration)

    Time frame: up to 72 hours after last drug administration of each treatment

  11. Vz/F,ss (apparent volume of distribution of the analyte in plasma at steady state after extravascular multiple dose administration)

    Time frame: up to 72 hours after last drug administration of each treatment

  12. PTF (Peak-Trough Fluctuation)

    Time frame: up to 72 hours after last drug administration of each treatment

  13. AUC0-tz,ss (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)

    Time frame: up to 72 hours after last drug administration of each treatment

  14. Number of patients with adverse events

    Time frame: up to day 76

  15. Number of patients with clinically relevant changes in Vital Signs (Blood Pressure, Pulse rate)

    Time frame: up to day 76

  16. Number of patients with clinically relevant changes in 12-lead electrocardiogram

    Time frame: up to day 76

  17. Number of patients with clinically relevant changes in laboratory tests

    Time frame: up to day 76

  18. Assessment of tolerability by the investigator on a 4-point scale

    Time frame: Day 8 of each treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007 and a primary completion of Sep 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2014
First posted
Aug 13, 2014
Start
Jun 2007
Primary completionActual
Sep 2007
Last update
Aug 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02215005
Responsible party
Sponsor
First posted
Aug 13, 2014
Start date
Jun 2007
Primary completion
Sep 2007
Last update
Aug 13, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Ramipril

Start the discussion